High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Every headline says Google is hemorrhaging its best AI minds to Anthropic and OpenAI, and that narrative has created one of the most exploitable gaps between fear and reality in the market right now.
DePuy Synthes, part of Johnson & Johnson MedTech, has acquired spine surgery company Expanding Innovations, adding new expandable interbody technologies to its portfolio. Johnson & Johnson has received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform in electrophysiology, expanding its ablation technology offering. For investors watching Johnson & Johnson, ticker NYSE:JNJ, these MedTech moves arrive with the stock at $253.04 and a value_score of 2. The company has recorded...
An endorsement from Buffett makes the Alphabet buy case even more compelling.
Micron just posted one of the most explosive quarters in semiconductor history, yet the stock has cratered nearly 14% in a single week as three distinct threats converge on the memory giant. Whether this selloff is a gift or a warning depends entirely on which scenario plays out next.
A 12% yield from a single BDC ETF sounds like a income investor's dream, but the fee stack, a payout ratio above 100%, and two consecutive distribution cuts inside the fund tell a different story about who actually keeps the money.
Amid the AI power boom, Constellation Energy wants to lead the small modular reactor (SMR) race with innovative bets.
Synopsys makes the software every chipmaker needs, so it profits regardless of who wins the AI race. Yet its stock fell after a strong quarter, and the reason isn’t obvious from the numbers alone.
The MLP has plenty of fuel to continue rallying.
Apple and Amazon posted identical revenue growth last quarter, yet the two companies are betting on opposite visions of the future. Which one actually protects your portfolio through a choppy back half of 2026?
TSMC and ASML are two of the most important companies in the semiconductor value chain.
Merck (NYSE:MRK) received FDA approval for Lipfendra (enlicitide), the first oral PCSK9 cholesterol-lowering drug. Lipfendra introduces an oral option for patients who have so far relied on injectable PCSK9 therapies. The approval expands Merck’s presence in cardiovascular medicine as key products approach patent expirations. Merck, trading around $127.5, is adding Lipfendra to its portfolio at a time when NYSE:MRK has posted a 64.8% return over the past year and 92.2% over five years. The...
Bloom Energy landed a $1.7 billion AI infrastructure deal. So why didn't the market react positively?
One trades at a 12x earnings multiple while the other generates triple the revenue.
Electricity demand just broke out of a 15-year flat line, and most investors are still pricing renewable stocks like nothing changed. Three names stand out this July, each for a very different reason.
The massive IPO has paved the way for SpaceX stock to underperform in the years ahead.
A sub-1% yield sounds like a reason to scroll past, but three companies are quietly compounding their payouts at rates that turn today's modest income into a serious cash stream within a decade.
TSMC's earnings announcement should light a fire in the AI investment theme.
Royal Caribbean still checks the most boxes.
BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.
These five financially strong industrial stocks are powering the AI infrastructure boom while keeping debt under control.
TSMC turned in another strong quarter and upped its guidance.
One stock stands out as the better buy.
The software giant is better positioned for the agentic AI era than Wall Street thinks.
A new Deutsche Bank report highlights how defense spending bolstered the shekel and a weak yen helped Japan have the cheapest iPhones in the world.
Investing.com -- Here are the biggest analyst moves in the area of artificial intelligence (AI) for this week.
Tesla shares are trading for less than $400, but one fast-growing restaurant chain looks like the better stock to buy.
Shares in Aehr Test Systems Inc. (NASDAQ:AEHR) jumped by 11.6 percent week-on-week, as investors increased their exposure after management posted a highly optimistic outlook for fiscal year 2027, thanks to the continued strong demand for semiconductor testing. In an updated report last week, the company said that it is targeting to grow its revenues during […]
After a massive run-up, Intel shares may be reversing course.
Yes, investors can find bargains in today's market, especially in the consumer sector.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
